Skip to main content
Top
Published in: Supportive Care in Cancer 11/2011

01-11-2011 | Original Article

Nutritional status of patients with locally advanced pancreatic cancer: a pilot study

Authors: Leah M. Ferrucci, Diana Bell, Jennifer Thornton, Glenda Black, Ruth McCorkle, Douglas C. Heimburger, Muhammad Wasif Saif

Published in: Supportive Care in Cancer | Issue 11/2011

Login to get access

Abstract

Purpose

Nutritional status may influence quality of life and prognosis among pancreatic cancer patients, yet few studies describe measures of nutritional status during treatment. We evaluated the nutritional status of locally advanced pancreatic cancer (LAPC) patients undergoing chemoradiotherapy who received baseline nutritional assessment and counseling.

Methods

Fourteen newly diagnosed LAPC patients enrolled in phase I/II trials of capecitabine with concomitant radiotherapy were assessed for baseline clinical nutrition measures (body mass index, albumin, weight loss, total energy, and protein intake). Participants completed the Anorexia/Cachexia Subscale (A/CS) questionnaire at baseline and during the 6 weeks of treatment. We evaluated associations between baseline characteristics and subsequent A/CS scores with linear regression and changes in A/CS were assessed with the paired t test.

Results

We observed a statistically significant increase in mean A/CS between baseline [24.9, standard deviation (SD) = 9.7] and end of treatment (29.9, SD = 6.2). Controlling for baseline A/CS score, only weight loss greater than 5% of body weight over 1 month was associated with A/CS scores at 6 weeks (β = 10.558, standard error = 3.307, p value = 0.009) and mean A/CS scores during the last 3 weeks of treatment (β = 12.739, standard error = 2.251, p value = 0.001).

Conclusions

After 6 weeks of chemoradiotherapy, LAPC patients reported a statistically significant improvement in appetite and weight concerns. Increases in AC/S scores were associated with higher baseline A/CS scores and weight loss of 5% or more during 1 month. Further research is needed to determine the impact of nutritional support during treatment, as improvements in this domain may impact LAPC patients' overall quality of life.
Literature
1.
go back to reference American Cancer Society (2009) Cancer facts and figures 2009. American Cancer Society, Atlanta American Cancer Society (2009) Cancer facts and figures 2009. American Cancer Society, Atlanta
2.
go back to reference Altekruse SF KC, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK (eds) SEER cancer statistics review, 1975–2007, http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010 Altekruse SF KC, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK (eds) SEER cancer statistics review, 1975–2007, http://​seer.​cancer.​gov/​csr/​1975_​2007/​, based on November 2009 SEER data submission, posted to the SEER web site, 2010
3.
go back to reference Bauer JD, Capra S (2005) Nutrition intervention improves outcomes in patients with cancer cachexia receiving chemotherapy—a pilot study. Support Care Cancer 13:270–274PubMedCrossRef Bauer JD, Capra S (2005) Nutrition intervention improves outcomes in patients with cancer cachexia receiving chemotherapy—a pilot study. Support Care Cancer 13:270–274PubMedCrossRef
4.
go back to reference Berenstein EG, Ortiz Z (2005) Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev (2):CD004310 Berenstein EG, Ortiz Z (2005) Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev (2):CD004310
5.
go back to reference Bosaeus I, Daneryd P, Lundholm K (2002) Dietary intake, resting energy expenditure, weight loss and survival in cancer patients. J Nutr 132:3465S–3466SPubMed Bosaeus I, Daneryd P, Lundholm K (2002) Dietary intake, resting energy expenditure, weight loss and survival in cancer patients. J Nutr 132:3465S–3466SPubMed
7.
go back to reference Bozzetti F (2009) Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients. Support Care Cancer 17:279–284PubMedCrossRef Bozzetti F (2009) Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients. Support Care Cancer 17:279–284PubMedCrossRef
8.
go back to reference Davidson W, Ash S, Capra S, Bauer J (2004) Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin Nutr 23:239–247PubMedCrossRef Davidson W, Ash S, Capra S, Bauer J (2004) Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin Nutr 23:239–247PubMedCrossRef
9.
go back to reference Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO Jr, Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlia C, Rosenbaum C, Silverstein MN, Skeel RT, Sponzo RW, Tormey DC (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69:491–497PubMedCrossRef Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO Jr, Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlia C, Rosenbaum C, Silverstein MN, Skeel RT, Sponzo RW, Tormey DC (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69:491–497PubMedCrossRef
10.
go back to reference Dobrila Dintinjana R, Guina T, Krznaric Z (2008) Nutritional and pharmacologic support in patients with pancreatic cancer. Coll Antropol 32:505–508PubMed Dobrila Dintinjana R, Guina T, Krznaric Z (2008) Nutritional and pharmacologic support in patients with pancreatic cancer. Coll Antropol 32:505–508PubMed
11.
go back to reference Falconer JS, Fearon KC, Plester CE, Ross JA, Carter DC (1994) Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 219:325–331PubMedCrossRef Falconer JS, Fearon KC, Plester CE, Ross JA, Carter DC (1994) Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 219:325–331PubMedCrossRef
12.
go back to reference Goonetilleke KS, Hathurusinghe HR, Burden S, Siriwardena AK (2008) Nutritional and anthropometric assessment of the scope for dietary optimization during staging prior to pancreaticoduodenectomy. Jop 9:415–421PubMed Goonetilleke KS, Hathurusinghe HR, Burden S, Siriwardena AK (2008) Nutritional and anthropometric assessment of the scope for dietary optimization during staging prior to pancreaticoduodenectomy. Jop 9:415–421PubMed
13.
go back to reference Gupta R, Ihmaidat H (2003) Nutritional effects of oesophageal, gastric and pancreatic carcinoma. Eur J Surg Oncol 29:634–643PubMedCrossRef Gupta R, Ihmaidat H (2003) Nutritional effects of oesophageal, gastric and pancreatic carcinoma. Eur J Surg Oncol 29:634–643PubMedCrossRef
14.
go back to reference Johansson U, Rasmussen HH, Mowe M, Staun M (2009) Clinical nutrition in medical gastroenterology: room for improvement. Clin Nutr 28:129–133PubMedCrossRef Johansson U, Rasmussen HH, Mowe M, Staun M (2009) Clinical nutrition in medical gastroenterology: room for improvement. Clin Nutr 28:129–133PubMedCrossRef
15.
go back to reference Maltoni M, Nanni O, Scarpi E, Rossi D, Serra P, Amadori D (2001) High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. Ann Oncol 12:289–300PubMedCrossRef Maltoni M, Nanni O, Scarpi E, Rossi D, Serra P, Amadori D (2001) High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. Ann Oncol 12:289–300PubMedCrossRef
16.
go back to reference Moses AW, Slater C, Preston T, Barber MD, Fearon KC (2004) Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 90:996–1002PubMedCrossRef Moses AW, Slater C, Preston T, Barber MD, Fearon KC (2004) Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 90:996–1002PubMedCrossRef
17.
go back to reference Mowe M, Bosaeus I, Rasmussen HH, Kondrup J, Unosson M, Rothenberg E, Irtun O (2008) Insufficient nutritional knowledge among health care workers? Clin Nutr 27:196–202PubMedCrossRef Mowe M, Bosaeus I, Rasmussen HH, Kondrup J, Unosson M, Rothenberg E, Irtun O (2008) Insufficient nutritional knowledge among health care workers? Clin Nutr 27:196–202PubMedCrossRef
18.
go back to reference Nitenberg G, Raynard B (2000) Nutritional support of the cancer patient: issues and dilemmas. Crit Rev Oncol Hematol 34:137–168PubMedCrossRef Nitenberg G, Raynard B (2000) Nutritional support of the cancer patient: issues and dilemmas. Crit Rev Oncol Hematol 34:137–168PubMedCrossRef
19.
go back to reference Oettle H, Arnold D, Hempel C, Riess H (2000) The role of gemcitabine alone and in combination in the treatment of pancreatic cancer. Anticancer Drugs 11:771–786PubMedCrossRef Oettle H, Arnold D, Hempel C, Riess H (2000) The role of gemcitabine alone and in combination in the treatment of pancreatic cancer. Anticancer Drugs 11:771–786PubMedCrossRef
20.
go back to reference Pelzer U, Arnold D, Govercin M, Stieler J, Doerken B, Riess H, Oettle H (2010) Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study. BMC Cancer 10:86PubMedCrossRef Pelzer U, Arnold D, Govercin M, Stieler J, Doerken B, Riess H, Oettle H (2010) Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study. BMC Cancer 10:86PubMedCrossRef
21.
go back to reference Ravasco P (2009) Cancer and nutrition: key determinants of quality of life. Eur J Cancer 45(Suppl 1):409PubMedCrossRef Ravasco P (2009) Cancer and nutrition: key determinants of quality of life. Eur J Cancer 45(Suppl 1):409PubMedCrossRef
22.
go back to reference Ravasco P, Monteiro Grillo I, Camilo M (2007) Cancer wasting and quality of life react to early individualized nutritional counselling! Clin Nutr 26:7–15PubMedCrossRef Ravasco P, Monteiro Grillo I, Camilo M (2007) Cancer wasting and quality of life react to early individualized nutritional counselling! Clin Nutr 26:7–15PubMedCrossRef
23.
go back to reference Ravasco P, Monteiro-Grillo I, Marques Vidal P, Camilo ME (2005) Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck 27:659–668PubMedCrossRef Ravasco P, Monteiro-Grillo I, Marques Vidal P, Camilo ME (2005) Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck 27:659–668PubMedCrossRef
24.
go back to reference Ribaudo JM, Cella D, Hahn EA, Lloyd SR, Tchekmedyian NS, Von Roenn J, Leslie WT (2000) Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Qual Life Res 9:1137–1146PubMedCrossRef Ribaudo JM, Cella D, Hahn EA, Lloyd SR, Tchekmedyian NS, Von Roenn J, Leslie WT (2000) Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Qual Life Res 9:1137–1146PubMedCrossRef
25.
go back to reference Saif MW, Black G, Roy S, Bell D, Russo S, Eloubeidi MA, Steg A, Johnson MR, Zelterman D, Diasio RB (2007) Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. Cancer J 13:247–256PubMedCrossRef Saif MW, Black G, Roy S, Bell D, Russo S, Eloubeidi MA, Steg A, Johnson MR, Zelterman D, Diasio RB (2007) Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. Cancer J 13:247–256PubMedCrossRef
26.
go back to reference Saif MW, Eloubeidi MA, Russo S, Steg A, Thornton J, Fiveash J, Carpenter M, Blanquicett C, Diasio RB, Johnson MR (2005) Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol 23:8679–8687PubMedCrossRef Saif MW, Eloubeidi MA, Russo S, Steg A, Thornton J, Fiveash J, Carpenter M, Blanquicett C, Diasio RB, Johnson MR (2005) Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol 23:8679–8687PubMedCrossRef
27.
go back to reference Thoresen L, Rothenberg E, Beck AM, Irtun O (2008) Doctors and nurses on wards with greater access to clinical dietitians have better focus on clinical nutrition. J Hum Nutr Diet 21:239–247PubMedCrossRef Thoresen L, Rothenberg E, Beck AM, Irtun O (2008) Doctors and nurses on wards with greater access to clinical dietitians have better focus on clinical nutrition. J Hum Nutr Diet 21:239–247PubMedCrossRef
28.
go back to reference Uomo G, Gallucci F, Rabitti PG (2006) Anorexia-cachexia syndrome in pancreatic cancer: recent development in research and management. Jop 7:157–162PubMed Uomo G, Gallucci F, Rabitti PG (2006) Anorexia-cachexia syndrome in pancreatic cancer: recent development in research and management. Jop 7:157–162PubMed
29.
go back to reference Vansteenkiste JF, Vandebroek JE, Nackaerts KL, Weynants P, Valcke YJ, Verresen DA, Devogelaere RC, Marien SA, Humblet YP, Dams NL (2001) Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol 12:1221–1230PubMedCrossRef Vansteenkiste JF, Vandebroek JE, Nackaerts KL, Weynants P, Valcke YJ, Verresen DA, Devogelaere RC, Marien SA, Humblet YP, Dams NL (2001) Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol 12:1221–1230PubMedCrossRef
30.
go back to reference Wigmore SJ, Barber MD, Ross JA, Tisdale MJ, Fearon KC (2000) Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer 36:177–184PubMedCrossRef Wigmore SJ, Barber MD, Ross JA, Tisdale MJ, Fearon KC (2000) Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer 36:177–184PubMedCrossRef
31.
go back to reference Wigmore SJ, Plester CE, Richardson RA, Fearon KC (1997) Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer 75:106–109PubMedCrossRef Wigmore SJ, Plester CE, Richardson RA, Fearon KC (1997) Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer 75:106–109PubMedCrossRef
Metadata
Title
Nutritional status of patients with locally advanced pancreatic cancer: a pilot study
Authors
Leah M. Ferrucci
Diana Bell
Jennifer Thornton
Glenda Black
Ruth McCorkle
Douglas C. Heimburger
Muhammad Wasif Saif
Publication date
01-11-2011
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 11/2011
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-010-1011-x

Other articles of this Issue 11/2011

Supportive Care in Cancer 11/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine